Phase II Study of Dysplasix™ Intravaginal Suppositories in Patients Patients With High-Risk HPV and Mild Cervical Cytologic Abnormalities
A phase 2 trial of EGCG and Quinine Sulfate Vaginal Suppository in vaginal cancer, run by Amplexd Therapeutics, Inc., now recruiting.
Overview
Phase II Study of Dysplasix™ Intravaginal Suppositories in Patients Patients With High-Risk HPV and Mild Cervical Cytologic Abnormalities is a phase 2 interventional study registered as NCT07572396 by Amplexd Therapeutics, Inc., with 45 participants planned, started 2026-04-30 and due to reach its primary completion in 2026-12-27. Interventions recorded: EGCG and Quinine Sulfate Vaginal Suppository.
Setting
A Phase II, Randomized, Double-blind, Placebo-Controlled, Proof of Concept Study to Assess the Safety and Efficacy of Dysplasix™ Intravaginally-Administered Suppositories in Patients With High-Risk Human Papillomavirus (Hr-HPV) as Determined by HPV Testing, and Accompanied by Either (1) Atypical Squamous Cells of Undetermined Significance (ASC-US) or (2) Low-Grade Squamous Intraepithelial Lesions (LSIL), as Determined by Cytology
Phase
Phase 2
Sponsor
Amplexd Therapeutics, Inc.
Registry
Enrolled
45
Similar pages
not linked directly; found by shared links- TrialArtesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)
Shares Vaginal cancer and the tag pipeline.
- TrialImmunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years
Shares Vaginal cancer and the tag pipeline.